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Abstract
Objectives
To evaluate the clinical outcome and complications in the pediatric population who had sple-
nectomy at our institution, emphasizing the incidence of postplenectomy reactive thrombo-
cytosis (RT) and its clinical significance in children without underlying hematological
malignancies.
Materials and methods
The medical records of pediatric patients undergoing splenectomy were retrospectively
reviewed for the period 1999–2018. The following variables were analyzed: Demographic
parameters (age, sex), indications for surgery, operative procedures, preoperative and post-
operative platelet count (postplenectomy RT), the use of anticoagulant therapy, and postop-
erative complications. The patients were divided into two groups according to indications for
splenectomy: The non-neoplastic hematology group and the non-hematology group (sple-
nectomy for trauma or other spleen non-hematological pathology).
Results
Fifty-two pediatric (37 male and 15 female) patients who underwent splenectomy at our
institution were reviewed. Thirty-four patients (65%) were in the non-hematological group
(splenic rupture, cysts, and abscess) and 18 patients (35%) in the non-neoplastic hemato-
logical group (hereditary spherocytosis and immune thrombocytopenia). The two groups did
not differ significantly in regards to the patients’ age, sex, and preoperative platelet count
(P>0.05 for all variables). Forty-nine patients (94.2%) developed postplenectomy RT. The
percentages of mild, moderate and extreme thrombocytosis were 48.9%, 30.7%, and
20.4%, respectively. The comparisons of RT patients between the non-neoplastic
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hematology and the non-hematology group revealed no significant differences in regards to
the patients’ age, sex, preoperative and postoperative platelet counts, preoperative and
postoperative leukocyte counts, and the average length of hospital stay (P>0.05 for all vari-
ables). None of the patients from the cohort was affected by any thrombotic or hemorrhagic
complications.
Conclusions
We confirm that RT is a very common event following splenectomy, but in this study it was
not associated with clinically evident thrombotic or hemorrhagic complications in children
undergoing splenectomy for trauma, structural lesions or non-neoplastic hematological
disorders.
Introduction
Reactive thrombocytosis (RT) refers to thrombocytosis in the absence of a chronic myelopro-
liferative disease or myelodysplastic disorder. RT is associated with various medical conditions
including infections, inflammation, hemorrhage, trauma, or surgery [1]. RT can be either tran-
sient or sustained and is driven by increased production of thrombopoietin, catecholamines,
and various interleukins (e.g. IL-6 and IL-11) [2].
Postsplenectomy RT is a very common event affecting 75–90% patients undergoing the
splenectomy [3, 4]. The platelet counts after splenectomy usually increase 30–100%, with the
highest values in the period between 10 to 20 days postoperatively [5]. Thrombocytosis may
persist over the next 2–3 months in most cases but in a few patients, thrombocytosis persists
indefinitely [6].
Although it is well established that the size and function of platelets in RT are normal and
that their interactions with blood vessels remain qualitatively normal [1], RT has been occa-
sionally associated with an increased risk of thrombotic and hemorrhagic events in patients
undergoing splenectomy [7, 8]. The thrombogenic potential of RT following splenectomy in
children without underlying hematological malignancies (myeloproliferative disorders or
myelodysplastic syndromes) are still not clearly defined.
To clarify the incidence and short-term clinical course and possible complications related
to RT following splenectomy in the absence of hematological malignancies, we provide a single
institution experience with RT in the pediatric population undergoing elective or emergency
splenectomy.
Patients and methods
Patients and selection criteria
The data of all patients who underwent total splenectomy (urgent or elective) at our pediatric
surgical department between January 1999 and December 2018 were retrospectively reviewed.
The following data were analyzed: Demographic parameters (age, sex), indications for surgery,
operative procedures, preoperative and postoperative platelet count, the use of anticoagulant
therapy, and postoperative complications. The patients were followed over the first three
weeks postoperatively. According to indications for splenectomy and RT, the patients were
divided into the non-neoplastic hematology group and the non-hematology group.
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The inclusion criteria for both groups were (1) Patients aged < 16 years; (2) Patients under-
going total splenectomy; (3) Development of postsplenectomy thrombocytosis with platelet
count> 500,000/μL; (4) Patients without neoplastic (myeloproliferative and myelodysplastic)
hematological disorders.
All the clinical records were fully anonymized prior to the study. The Ethics Committee
(Institutional Review Board) of University Clinical Center Sarajevo approved the study and
waived informed consent request from the patients and their families (the number of approval:
#10-01-2-123/19).
Definitions and classifications
Total splenectomy was defined as a complete surgical removal of the spleen. Myeloproliferative
disorders were defined as any of several hematologic malignancies marked by the excess of
one or more types of white blood cells [9]. These disorders include polycythemia vera, essential
thrombocytosis, chronic myeloid leukemia (CML), and idiopathic myelofibrosis [9]. Myelo-
dysplastic syndromes were defined as any of a broad group of bone marrow disorders that are
characterized by an abnormal reduction in one or more lineages of circulating white blood
cells due to defective growth and maturation of blood-forming cells in the bone marrow with a
potential to progress to acute myelogenous leukemia (AML).
Thrombocytosis was defined as a platelet count>500,000/μL. Mild thrombocytosis was
defined as a platelet count >450,000/μL and <600,000/μL, moderate thrombocytosis a platelet
count>600,000/μL and<1,000,000/μL, and extreme thrombocytosis as a platelet count
>1,000,000/μL. The platelets were consecutively measured first ten postoperative days after
which three additional measurements (11th, 14th and 21st postoperative day) were done.
In an attempt to determine whether an association exists between RT and thrombotic or
hemorrhagic complications, one month after hospital discharge all the patients were contacted
for further investigations.
All platelet counts were performed on ABBOTT CELL DYN 3700 (Chicago, Illinois, USA)
counter, using EDTA anticoagulated fresh blood. The normal range of platelet counts for this
machine is 150,000 to 450,000/μL.
Statistical analysis
To evaluate the normality of the distribution of continuous variables, we used the Shapiro-
Wilk (SW) test. The student’s t-test was used to compare independent continuous variables
that followed the normal distribution. The Wilcoxon signed-rank test was used to test the dif-
ferences of paired data without the normal distribution. P-values < 0.05 were considered sig-
nificant. All the statistical analyses were performed using the Statistical Package for the Social
Sciences (SPSS) IBM Version 26 (SPSS) (UNICOM Systems, Inc.).
Results
The characteristics of the cohort are summarized in Table 1.
Fifty-two children with a mean age of 9.2 years (range, 0.6–14.5 years) had splenectomy at
our institution in the period 1999–2018. All patients were treated with an open splenectomy
approach and all received prophylactic antibiotics and pneumococcal vaccine. Among the
splenectomy children, 37 (71%) were male and 15 (29%) female patients (male/female ratio of
2.5:1). Severe spleen trauma (rupture) was the most common indication for splenectomy (29
patients, 55.8%), followed by non-neoplastic hematological disorders (18 patients, 34.6%).
Three patients (5.8%) had splenectomy for splenic hydatid cysts, and two (3.8%) had splenec-
tomy for multiple splenic abscesses. Among the patients with non-neoplastic hematological
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disorders, splenectomy was indicated for hereditary spherocytosis (HS) (n = 16) and immune
thrombocytopenia (ITP) (n = 2). Four patients (7.7%) developed postoperative non-throm-
botic complications including wound infection, wound hematoma and splenic fossa collection
(Table 1). None of the patients developed thrombotic or hemorrhagic complications during
the follow-up period. Neither postoperative death nor subsequent fatal infections were
observed in the cohort. Forty-nine patients (94.2%) developed a postplenectomy RT. The per-
centages of mild, moderate and extreme thrombocytosis were 48.9%, 30.7%, and 20.4%,
respectively. The comparisons between RT patients in non-neoplastic hematology and non-
hematology groups is shown in Table 2. In the non-neoplastic hematology group of patients, a
gradual increase in platelet count was observed from the first to sixth day after splenectomy.
After this period, the platelet count was gradually decreasing (Table 3). In the non-hematology
group of patients, the platelet count decreased in the first two days after splenectomy, probably
because of hemodilution but gradually increases starting at day three. From the sixth to the
eleventh day, RT has been reported in this group of patients, followed by a gradual decrease in
the platelet count, but RT persisted three weeks following splenectomy (Table 3). Although the
recorded platelet counts were greater and lasted longer in the non-hematological group com-
pared with the non-neoplastic hematological group, the difference was not significant
Table 1. The patients’ demographics, their perioperative characteristics, and indications for splenectomy.
Variable Overall Indications for splenectomy P-value
Non-neoplastic hematology
group
Non-hematology
group
The number of patients no. (%) 52
(100%)
18 (34.6%) 34 (65.4%) -
Mean age at surgery (yr) 9.0±1.84 9.2±1.22 8.6±2.08 0.12
Sex (% male) 37 (71%) 30 (81%) 7 (19%) 0.09
Preoperative platelet count 324 K/μL 332.5 K/μL 317.5 K/μL 0.98
Short-term adverse events (� 3 weeks) (wound infection, wound hematoma and splenic
fossa collection)
4 (7.7%) 1 (5.6%) 3 (8.8%) -
K/μL, kilo per microliter.
https://doi.org/10.1371/journal.pone.0237016.t001
Table 2. The comparative analysis of various clinical parameters between the two groups of the patients affected by reactive thrombocytosis.
Variable Overall Postplenectomy reactive thrombocytosis
Non-neoplastic hematology group Non-hematology group P-value
The number of patients no. (%) 49 (100%) 16 (32%) 33 (68%) -
Mean age at surgery (yr) 9.0±1.9 9.3±1.3 8.6±2.11 0.85
Sex (% male) 35 (71%) 29 (82%) 6 (18%) 0.08
Preoperative leukocyte count 12.54x109/L 9.43 x 109/L 13.42 x 109/L 0.13
Preoperative platelet count 329 333 325 0.91
Postoperative leukocyte count (K/μL)� 12.21x109/L 11.4 x 109/L 12.48 x 109/L 0.52
Postoperative platelet count (K/μL)� 716 586 846 0.47
Mild thrombocytosis no. (%) 24 (48.9%) 10 (42%) 14 (58%) -
Moderate thrombocytosis no. (%) 15 (30.7%) 4 (26%) 11 (74%) -
Extreme thrombocytosis no. (%) 10 (20.4%) 2 (20%) 8 (80%) -
Length of stay (day) 9.7 10.6 10.4 0.89
K/μL, kilo per microliter.
�The presented numbers are mean values that were recorded for these variables in the first 21 postoperative days.
https://doi.org/10.1371/journal.pone.0237016.t002
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(p = 0.21). Given that the international normalized ratio (INR) values were normal in all
patients with extreme RT, the majority of the patients with extreme RT (80%) did not receive
any antiplatelet or anticoagulant therapy. Only two patients received the treatment; one child
received a low-dose aspirin (5 mg/kg) until their platelet counts fell to the reference values
while the older pubertal child received a subcutaneous enoxaparin treatment.
Discussion
It is well known that the incidence of thrombocytosis shows an age-dependent pattern with
the highest reported occurrence in infants aged up to 24 months [10, 11]. Specifically, during
childhood, platelet counts greater than 500,000/μL may be seen in 13% of neonates at birth,
36% during the first month, particularly in low birth-weight infants, and 13% in 6 to 11
months of age [11]. The trend of a gradual decrease in platelet counts continues throughout
childhood and reaches normal levels by the age of 11 [11]. Thrombocytosis in children is
caused by the immaturity of their innate and/or adaptive immunity or more frequently by
infections [12]. We found no statistically significant difference in the age of children with RT
because splenectomized children in our cohort were on average older (9.2 years) and because
of the cause of thrombocytosis itself.
RT in childhood is usually associated with bacterial or viral infections; less frequent causes
include anemias (hemolytic or iron-deficiency), autoimmune diseases, cancers and drugs [11].
Since the spleen in healthy persons is a reservoir for approximately 1/3 of total body platelets,
splenectomy is a well-recognized cause of RT [3, 5, 13, 14]. Our study revealed a very high
(94%) prevalence of RT among the pediatric population undergoing splenectomy. Although
this prevalence appears to be high, it is in line with the previous studies that have been reported
in pediatric population [1, 3, 4, 13, 14]. In addition, splenectomy was found to be one of the
main causes of extreme RT [15]. In our study, the extreme thrombocytosis accounted for 20%
of all reported cases of postsplenectomy RT.
Another important finding from our study is a higher incidence of RT including extreme
RT in male patients, with the male/female ratio 2.5:1, which is in agreement with the previous
studies [16–18]. The reasons for male predominance can be partially explained by the synergis-
tic effects of sex hormones, especially androgens, on thrombopoiesis and androgen modula-
tion of platelet count and function [19].
Extreme thrombocytosis may predispose several complications including neurological
(vasomotor), thrombotic, and hemorrhagic [20]. However, in case of postsplenectomy RT, the
platelets retain their normal structure and function, the bone marrow is normal, and the inter-
action of platelets with the vessel wall remains normal. Therefore, the association of thrombo-
cytosis with complications such as thrombosis and hemorrhage appear to be related to
quantitative rather than qualitative platelet abnormalities [1, 20]. This was also confirmed in
our study given that the measured INR was normal in all cases including extreme RT. How-
ever, thrombotic complications have been occasionally reported in pediatric RT following
splenectomy for other reasons [21, 22].
Table 3. The comparison of platelet counts between the non-neoplastic hematology vs. non-hematology group.
Postplenectomy days
Variable 0 1 2 3 4 5 6 7 8 9 10 11 14 21
Platelet count in the non-neoplastic hematology group (K/μL) 294 347 384 448 479 609 675 502 505 511 497 485 460 420
Platelet count in the non-hematology group (K/μL) 343 314 322 378 376 497 619 749 951 974 985 992 760 665
K/μL, kilo per microliter.
https://doi.org/10.1371/journal.pone.0237016.t003
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Some observations suggest that leukocytosis may also increase the risk of thrombosis in
patients with myeloproliferative disorders [23], but no such association was found in patients
without myeloproliferative disorders. Among our patients, there were no cases of clinically
suggestive thrombosis including cases of portal splenic vein thrombosis (PSVT).
Previous studies have suggested that fatal thrombotic complications in adult patients with
postplenectomy thrombocytosis can be prevented by prophylactic anticoagulants or antiplate-
let drugs [24]. In contrast, studies that are more recent have shown a much lower rate of
thrombotic events in postsplenectomy adult patients, which did not differ significantly com-
pared to other postoperative groups [25]. The exceptions are patients with myeloproliferative
neoplasms in whom platelets are often morphologically and functionally abnormal with the
consequent increased risk of thrombosis and bleeding [26].
The treatment of asymptomatic infants and children with extreme RT is still controversial.
However, 80% of children with extreme RT in our study did not receive any antiplatelet or
anticoagulant therapy and had no any adverse event. These findings further support previous
studies that revealed a low risk of complications among this population [1, 27–29].
Our study has several limitations including its retrospective nature, single center experience
and small sample size. A longer follow-up period would provide valuable information on
potentially late thrombotic events among the postplenectomy children with persistent RT. In
addition, a postoperative ultrasound scans were not part of the routine checkups for occult
splenic and portal vein thrombosis, which may affect these patients [22]. Despite all the limita-
tions, we confirm that RT is a very common event following splenectomy, but in this study it
was not associated with clinically evident thrombotic or hemorrhagic complications in chil-
dren undergoing splenectomy for trauma, structural lesions or non-neoplastic hematological
disorders.
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